CBio evolved from a research-based operation into an early-stage drug development organisation. CBio develops and commercialises treatments for autoimmune diseases. CBio owns a worldwide exclusive licence for the chaperonin 10 intellectual property, which is recently identified as an important protein in innate immune diseases.

Sector: Health Care
Shares on Issue: 60,721,564
Current Market Capitalisation: $21,252,547
Website: http://www.cbio.com.au